phase iii squire trial in patients with nsclc treated with necitumumab
Published 9 years ago • 115 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:27
necitumumab effective antibody against egfr for squamous lung cancer patients?
-
10:54
new therapies for squamous nsclc
-
4:35
necitumumab in nsclc
-
1:38
necitumumab plus pembrolizumab: a viable alternative for nsclc
-
2:05
necitumumab in squamous nsclc
-
2:53
dr. reck discusses mss of lcss as prognostic and predictive factor for os in squire study
-
1:48
dr. fred hirsch on next steps for necitumumab in nsclc
-
6:28
pacific trial implications concerning nsclc mutations
-
4:30
rationale for ramucirumab in nsclc
-
2:25
dr. paz-ares on connection of egfr-expression and necitumumab response in nsclc
-
2:13
genomic testing expands with evolving lung cancer treatment paradigm
-
3:35
potential new biomarkers in lung cancer
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
21:12
squamous cell carcinoma of the lung: treatment options in first- and second line
-
4:49
tatton trial – savolitinib plus osimertinib in egfr-mutated, met-amplified nsclc | lecia sequist
-
7:41
repeat testing at progression of egfr nsclc
-
18:00
necitumumab: targeting egfr with next-generation antibodies - paul bunn
-
25:46
advances in squamous cell carcinoma
-
6:39
tki combinations in metastatic egfr lung cancer